Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
4
Neutral
1
Bullish
9
Bearish
36
Neutral
1
Bullish
9
Bearish
32
Neutral
0
Bullish
0
Bearish
4
Neutral
1
Bullish
9
Bearish
4
Neutral
1
Bullish
9
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Epigral Limited manufactures and sells chlor-alkali products and derivatives, including caustic soda, epichlorohydrin (ECH), CPVC resin and compounds, hydrogen peroxide, chloromethanes, and now expanding into epoxy resin, multipurpose specialty intermediates and downstream formulations through its Dahej integrated complex in Gujarat.
The company has approved a strategic INR600 crore capex for a 125,000 tpa epoxy resin and formulations facility and a multipurpose plant, with a pilot plant to be operational by Q2 FY27; over 50% of raw material value for epoxy will be internally supplied, strengthening backward integration and margin resilience.
Q1 FY27 results showed revenue of INR709 crores, up 15% year-on-year, EBITDA of INR179 crores (25% margin) and PAT of INR99 crores, reflecting volume growth and higher realizations despite global raw material and logistics disruption; ROCE softened due to capital work-in-progress and lower trailing earnings.
Epigral is positioned to serve rising domestic demand for epoxy in wind blades, automotive and construction, while expanding chlorotoluenes value chain to serve pharmaceuticals, agrochemical intermediates and water treatment chemicals; management expects domestic absorption first and selective exports to Europe post trade agreements.
Chemicals & Petrochemicals
Specialty Chemicals
3,873 Cr
High Risk
14.3
35.0
0.6
1.7
1,725.45
806.20
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
Epigral Ltd (EPIGRAL) is currently trading at 891.65 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Epigral Limited manufactures and sells chlor-alkali products and derivatives, including caustic soda, epichlorohydrin (ECH), CPVC resin and compounds, hydrogen peroxide, chloromethanes, and now expanding into epoxy resin, multipurpose specialty intermediates and downstream formulations through its Dahej integrated complex in Gujarat. The company has approved a strategic INR600 crore capex for a 125,000 tpa epoxy resin and formulations facility and a multipurpose plant, with a pilot plant to be operational by Q2 FY27; over 50% of raw material value for epoxy will be internally supplied, strengthening backward integration and margin resilience. Q1 FY27 results showed revenue of INR709 crores, up 15% year-on-year, EBITDA of INR179 crores (25% margin) and PAT of INR99 crores, reflecting volume growth and higher realizations despite global raw material and logistics disruption; ROCE softened due to capital work-in-progress and lower trailing earnings. Epigral is positioned to serve rising domestic demand for epoxy in wind blades, automotive and construction, while expanding chlorotoluenes value chain to serve pharmaceuticals, agrochemical intermediates and water treatment chemicals; management expects domestic absorption first and selective exports to Europe post trade agreements.
Over the past 52 weeks, Epigral Ltd has traded between a low of ₹806.20 and a high of ₹1,725.45. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Epigral Ltd has a market capitalization of approximately 3,872.80. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Epigral Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 14.29 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 3,872.80 Cr, Epigral Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Epigral Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Epigral Ltd is 14.29. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Epigral reported standalone net profit (PAT) of ₹99.18 crore for the quarter ended June 30, 2026.
The filing shows revenue from operations of ₹705.36 crore (total income ₹709.46 crore) and standalone PAT of ₹99.18 crore for the quarter ended June 30, 2026; consolidated PAT was ₹99.74 crore.
Epigral reported revenue from operations of ₹709 crore and PAT of ₹99 crore for the quarter ended June 30, 2026.
The stock jumped after PAT more than doubled sequentially to Rs 81.93 crore and EBITDA margin improved to 23% from 17% in Q3 FY26, alongside record quarterly revenue.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
5738.10 | 4,325 Cr | 42.59 | 4.17 | 0.44 | 8.43 | 12.26 | 7.42 | ||
713.05 | 4,220 Cr | 96.75 | 9.43 | 0.16 | 0.00 | 0.00 | — | ||
150.60 | 4,185 Cr | 33.30 | 2.11 | 0.20 | 4.00 | 4.35 | 3.65 | ||
3328.50 | 4,013 Cr | 69.59 | 9.04 | 0.02 | 5.69 | 8.71 | 4.99 | ||
897.70 | 3,873 Cr | 14.29 | 1.74 | 0.56 | 14.94 | 14.69 | 7.73 | ||
562.75 | 3,788 Cr | 25.31 | 3.54 | 0.05 | 13.31 | 14.64 | 7.17 | ||
1572.10 | 3,677 Cr | 58.45 | 4.51 | 0.13 | 7.72 | 9.23 | 5.62 | ||
| Median: 7 Co. | — | 897.70 | 4,013 Cr | 42.59 | 4.17 | 0.16 | 7.72 | 9.23 | 6.40 |
